Insulet FY2028 EPS Forecast Boosted by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Analysts at Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for shares of Insulet in a report released on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $7.80 for the year, up from their previous forecast of $7.75. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share.

A number of other equities research analysts also recently weighed in on PODD. BTIG Research raised their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Piper Sandler increased their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Raymond James boosted their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Insulet stock opened at $266.92 on Wednesday. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The firm’s fifty day moving average price is $243.21 and its 200-day moving average price is $212.74. The stock has a market cap of $18.72 billion, a P/E ratio of 45.71, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Institutional Trading of Insulet

Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in shares of Insulet in the 2nd quarter worth about $99,978,000. Baillie Gifford & Co. grew its holdings in shares of Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after acquiring an additional 443,783 shares during the period. Mizuho Securities USA LLC raised its position in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after acquiring an additional 320,416 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP boosted its position in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.